Ophthalmic Preparation Patents (Class 424/78.04)
-
Patent number: 11771766Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.Type: GrantFiled: April 30, 2020Date of Patent: October 3, 2023Assignees: Taiwan Liposome Co., Ltd., TLC Biopharmaceuticals, Inc.Inventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
-
Patent number: 11717532Abstract: Described herein are methods of treating wounds, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan wherein the soluble or derivatized chitosan when administered contacts the wound, thereby treating the wound.Type: GrantFiled: March 16, 2018Date of Patent: August 8, 2023Assignee: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann, Ruth Baxter
-
Patent number: 11623008Abstract: Excipient compositions including a combination of excipients for mucoadhesive pharmaceutical compositions that improve mucoadhesiveness power, as well as release of and adhesion time of suitable active pharmaceutical ingredients (APIs) are disclosed. The excipient compositions include an aqueous solution with a synergistic combination of polymers, such as, for example amylopectin, pullulan, hyaluronic acid, and tamarind xyloglucan, among others. These polymers have been demonstrated to improve the release of as well as the adhesion time of APIs onto mucosa membrane. Mucoadhesive pharmaceutical compositions that include excipient compositions include suitable APIs, such as, for example analgesics, anesthetics, anthelmintics, anti-allergic agents, anti-fungals, antihistamines, anti-inflammatory agents, antimigraine agents, and hormones, among others. Mucoadhesive pharmaceutical compositions including excipient compositions are employed in the treatment of a plurality of mucous membrane diseases.Type: GrantFiled: August 19, 2015Date of Patent: April 11, 2023Assignee: Professional Compounding Centers of AmericaInventor: Daniel Banov
-
Patent number: 11576973Abstract: The present invention provides aqueous formulations containing an anti-infection agent, a biocompatible polysaccharide, an osmotic pressure regulator, a pH regulator, and water, wherein a gel containing the therapeutic agent is formed in situ upon instillation of the formulations onto the skin and a body cavity of a subject. The formulations of this invention are useful for treating infectious diseases of skin or a body cavity (e.g., eye, nose, or vagina) of a subject.Type: GrantFiled: October 25, 2016Date of Patent: February 14, 2023Assignee: IVIEW Therapeutics, Inc.Inventors: Bo Liang, Gang Wei, John J. Baldwin
-
Patent number: 11513257Abstract: The invention relates to an ophthalmic product which comprises a sealed and autoclave-sterilized lens package including (1) a post-autoclave packaging solution containing a polymeric surfactant having an HLB value of from about 11 to about 16 and a Mn of from about 800 to about 20,000 Daltons and (2) a readily-usable silicone hydrogel (SiHy) contact lens immersed in the packaging solution. The readily-usable SiHy contact lens comprises the polymeric surfactant thereon providing an excellent wettability to the readily-usable SiHy contact lens directly out of the lens package, and also the leachable polymeric surfactant which is physically distributed in the polymer matrix of the SiHy contact lens and can be released to the eye of a patient for at least 7 days of daily wear and to replenish the lens surface-bound polymeric surfactant to provide sustainable wettabilities to the contact lens and the eye.Type: GrantFiled: December 15, 2020Date of Patent: November 29, 2022Assignee: Alcon Inc.Inventors: Ying Zheng, Jang-Shing Chiou, Jinbo Dou, Yuan Chang, Junhao Ge, Steve Yun Zhang, Li Yao, Karen Belinda Sentell, Ye Hong
-
Patent number: 11406592Abstract: An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.Type: GrantFiled: October 23, 2018Date of Patent: August 9, 2022Assignee: Mati Therapeutics Inc.Inventors: Eugene de Juan, Jr., Cary Reich, Stephen Boyd, Hanson S. Gifford, III, Mark Deem
-
Patent number: 11344538Abstract: The invention provides methods for the treatment of myopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant, a viscosity agent, a polyol and/or a selective ?-2 adrenergic receptor agonist.Type: GrantFiled: February 20, 2020Date of Patent: May 31, 2022Assignee: LENZ THERAPEUTICS, INC.Inventor: Gerald Horn
-
Patent number: 11224602Abstract: The present disclosure includes compositions of a semi-crystalline or crystalline pharmaceutically active agent dispersed in a polymer matrix, in which the active agent is less degraded and, therefore, has lower level of impurities. The present disclosure further includes a method of reducing or preventing physical and chemical degradation of a semi-crystalline or crystalline active agent pharmaceutically active agent dispersed in a polymer matrix. A method of preparation of the composition is also included in this disclosure.Type: GrantFiled: January 9, 2019Date of Patent: January 18, 2022Assignee: ForSight Vision5, Inc.Inventors: Logan Stark, Rachna Jain, Ravi Srinivasan, Cary J. Reich, Carlos Schuler
-
Patent number: 11129862Abstract: The present invention relates to compositions providing improved substantivity, comfort and/or feel to the eye upon application. The present invention further relates to compositions comprising a cellulose derivative in combination with tamarind seed extract and hyaluronic acid in ratios that mimic the physical properties of human tears on the eye.Type: GrantFiled: August 27, 2018Date of Patent: September 28, 2021Assignee: Johnson & Johnson Consumer Inc.Inventors: Mingqi Bai, Kenneth T. Holeva
-
Patent number: 11045432Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.Type: GrantFiled: August 25, 2016Date of Patent: June 29, 2021Assignee: Harrow IP, LLCInventors: John Scott Karolchyk, Mark L. Baum
-
Patent number: 10898738Abstract: Provided herein are compositions and methods for improving a visual function, e.g., eyesight, eye strain, blurred vision, dry eye, retinal function, presbyopia, or Visual Display Terminal (VDT) syndrome, that is safe for long-term intake and ensures effective improvement of visual function. The compositions include a nicotinamide mononucleotide (structure shown below) as an active ingredient.Type: GrantFiled: September 13, 2017Date of Patent: January 26, 2021Inventors: Megumi Tanaka, Tsunemaru Tanaka
-
Patent number: 10888631Abstract: The present invention relates to a method for sterilisation of phospholipid suspensions, useful in the preparation of ultrasound contrast agent precursors comprising phospholipid-stabilised perfluorobutane microbubbles. The method provides sterility assurance, without undue thermal degradation of the phospholipid. The method is also amenable to commercial scale manufacture. Also provided are methods of preparing kits and ultrasound contrast agents incorporating the sterilisation method of the invention.Type: GrantFiled: June 26, 2015Date of Patent: January 12, 2021Assignee: GE HEALTHCARE ASInventors: Svein Kvale, Ingrid Henriksen, Ole Johannes Tokerud, Per Sontum
-
Patent number: 10639274Abstract: A lubricant formulation of carbamoylethyl katira and a microwave assisted process for the preparation of the lubricant formulation of carbamoylethyl katira. The lubricant formulation of carbamoylethyl katira having antibacterial activity useful for eye lubricant based formulations, treatment of dry eye disease syndrome, etc.Type: GrantFiled: August 5, 2016Date of Patent: May 5, 2020Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Vikas Rana, Radhika Sharma, Sunil Kamboj, Kuldeep Singh, Sarasija Suresh
-
Patent number: 10617763Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a cryoprotectant. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.Type: GrantFiled: January 8, 2018Date of Patent: April 14, 2020Assignee: PRESBYOPIA THERAPIES, LLCInventors: Gerald Horn, Lee Nordan
-
Patent number: 10595532Abstract: The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.Type: GrantFiled: August 6, 2018Date of Patent: March 24, 2020Assignee: FXS VENTURES, LLCInventor: Francis X. Smith
-
Patent number: 10532026Abstract: The present invention is an aqueous solution which contains two types of methyl celluloses, polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. The composition of the present invention maintains a low viscosity around room temperature, but the composition is suddenly increased in the viscosity due to heat around the body temperature and has thixotropy even after gelation.Type: GrantFiled: August 23, 2018Date of Patent: January 14, 2020Assignee: WAKAMOTO PHARMACEUTICAL CO., LTD.Inventors: Takeshi Yamamura, Ayaka Yamamuro, Emi Izukura, Moto Kimura, Tomohiro Otsuka
-
Patent number: 10493155Abstract: The present invention relates to a heat-sterilized aqueous composition comprising a solubilized chitosan and glycerol. It also relates to a process of preparation of the same, as well as the use thereof, including compositions useful for the prevention and treatment of dry eye syndrome and arthritic diseases or disorders.Type: GrantFiled: October 28, 2015Date of Patent: December 3, 2019Assignee: LABORATOIRE MEDIDOM SAInventors: Leila Yolanda Bossy, Alessandro Di Napoli
-
Patent number: 10451612Abstract: Aspects and embodiments of the instant disclosure provide a particle and/or intracellular organelle alignment agent for a particle analyzer used to analyze particles contained in a sample. An exemplary particle and/or intracellular organelle alignment agent includes an aqueous solution, a viscosity modifier, and/or a buffer.Type: GrantFiled: September 12, 2016Date of Patent: October 22, 2019Assignee: Iris International, Inc.Inventors: Gregory A. Farrell, Bart J. Wanders, Thomas H. Adams, Warren Groner, Xiaodong Zhao
-
Patent number: 10398707Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.Type: GrantFiled: October 2, 2017Date of Patent: September 3, 2019Assignee: Allergan, Inc.Inventor: Patrick M. Hughes
-
Patent number: 10130652Abstract: The present invention relates to the use as an anti-inflammatory of tamarind seed polysaccharide (TSP) and to anti-inflammatory compositions which contain it as active ingredient. Anti-inflammatory compositions containing TSP are particularly useful for topical administration in the treatment of inflammatory diseases of the skin and mucosa.Type: GrantFiled: May 23, 2011Date of Patent: November 20, 2018Assignee: INDENA S.P.A.Inventors: Andrea Giori, Sabrina Arpini, Stefano Togni
-
Patent number: 10064410Abstract: The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.Type: GrantFiled: January 23, 2017Date of Patent: September 4, 2018Assignee: FXS VENTURES, LLCInventor: Francis X. Smith
-
Patent number: 10058615Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.Type: GrantFiled: February 8, 2017Date of Patent: August 28, 2018Assignee: NOVALIQ GMBHInventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew, Bastian Theisinger, Sonja Theisinger
-
Patent number: 9907750Abstract: The purpose of the present invention is to provide a technique for formulating a two-layer separation-type ophthalmic solution in which, during storage, an aqueous layer and an oil-containing layer containing squalane are separated from each other, wherein it is possible to homogeneously disperse the oil-containing layer in the aqueous layer while suppressing foaming by shaking the ophthalmic solution before administration, and the homogeneous dispersed state is maintained in a stable manner at least until administration. A two-layer separation-type ophthalmic solution containing squalane and water, wherein hyaluronic acid and/or a salt thereof and polyvinyl alcohol are contained in the ophthalmic solution and the polyvinyl alcohol content is set to 0.025 to 0.Type: GrantFiled: March 18, 2014Date of Patent: March 6, 2018Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventor: Shirou Sawa
-
Patent number: 9872927Abstract: The invention relates to a water-based biocompatible non-cytotoxic preparation for the selective staining of internal limiting membrane (ILM) and/or epiretinal membranes (ERM) in the human or animal eye, and to a kit containing said water-based preparation according to the invention.Type: GrantFiled: September 29, 2016Date of Patent: January 23, 2018Assignee: FLUORON GMBHInventors: Christian Lingenfelder, Bastian Theisinger, Wilfried Hiebl, Nadine Hagedorn
-
Patent number: 9795560Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.Type: GrantFiled: January 31, 2014Date of Patent: October 24, 2017Assignee: Ocularis Pharma, LLCInventor: Alan Meyer
-
Patent number: 9775846Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.Type: GrantFiled: November 21, 2016Date of Patent: October 3, 2017Assignee: Allergan, Inc.Inventor: Patrick M. Hughes
-
Patent number: 9765340Abstract: RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.Type: GrantFiled: September 2, 2016Date of Patent: September 19, 2017Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
-
Patent number: 9707238Abstract: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.Type: GrantFiled: August 10, 2015Date of Patent: July 18, 2017Assignee: Allergan, Inc.Inventors: James Chang, Patrick Hughes, Chin-Ming Chang
-
Patent number: 9642360Abstract: Cationic antimicrobial polymers have been synthesized by a bulk addition polymerization of a nucleophilic agent comprising two tertiary amines and an electrophilic agent that comprises two leaving groups and an aromatic ring between the leaving groups. The reaction solvent for the polymerization is chosen to allow precipitation of the cationic polymer at the polymerization temperature, thereby limiting molecular weight. Quaternization and polymerization occur concurrently. The cationic polymers can be highly active against Gram-negative and Gram-positive microbes, and/or fungi. The cationic polymers can also be non-hemolytic and non-cytotoxic at the effective concentration against the microbes.Type: GrantFiled: June 25, 2015Date of Patent: May 9, 2017Assignees: International Business Machines Corporation, Agency For Science, Technology And ResearchInventors: Julian M. W. Chan, James L. Hedrick, Robert J. Ono, Jye Yng Teo, Yi Yan Yang, Mu San Zhang
-
Patent number: 9636355Abstract: An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.Type: GrantFiled: September 22, 2011Date of Patent: May 2, 2017Assignee: Theo Holdings, LLCInventor: John M. Szabocsik
-
Patent number: 9585394Abstract: The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.Type: GrantFiled: February 29, 2016Date of Patent: March 7, 2017Assignee: FXS VENTURES, LLCInventor: Francis X. Smith
-
Patent number: 9572859Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.Type: GrantFiled: April 5, 2013Date of Patent: February 21, 2017Assignee: Allergan, Inc.Inventors: Patrick M. Hughes, Orest Olejnik, Scott M. Whitcup, James A. Burke
-
Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
Patent number: 9480696Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.Type: GrantFiled: May 4, 2012Date of Patent: November 1, 2016Assignee: TRUSTEES OF BOSTON UNIVERSITYInventors: James J. Collins, Kyle R. Allison, Mark P. Brynildsen -
Patent number: 9452177Abstract: The present invention relates to compounds and methods for reducing intraocular pressure and treating ocular hypertension in a subject.Type: GrantFiled: March 10, 2009Date of Patent: September 27, 2016Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Galina D. Kutuzova, Paul L. Kaufman, B'Ann True Gabelt
-
Patent number: 9453220Abstract: RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.Type: GrantFiled: January 23, 2014Date of Patent: September 27, 2016Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: John M. Yanni, John E. Chatterton, Daniel A. Gamache, Steven T. Miller
-
Patent number: 9427737Abstract: Oil compositions and methods for use in droplet formation or in spacing of droplets are disclosed. The oil compositions may include a combination, such as a silicone oil and a fluorine-containing compound. The droplets can contain analytes (e.g., nucleic acids) and may be used for molecular reactions (e.g., digital PCR) and detection.Type: GrantFiled: December 12, 2013Date of Patent: August 30, 2016Assignee: Bio-Rad Laboratories, Inc.Inventors: Nicholas Jack Heredia, Anthony J. Makarewicz, Jr.
-
Patent number: 9421184Abstract: The present invention relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof to a patient in need of such a treatment. The invention further relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof in combination with one or more additional anti-inflammatory active agents to a patient in need of such a treatment.Type: GrantFiled: July 28, 2014Date of Patent: August 23, 2016Assignee: ITALFARMACO S.P.A.Inventors: Valentina Saccone, Silvia Consalvi, Pier Lorenzo Puri, Paolo Mascagni
-
Patent number: 9393243Abstract: Embodiments of the invention provide pharmaceutical compositions of ciprofloxacin formulated for topical application to a body surface and for having at least localized antibacterial activity. In some embodiments, the compositions are further formulated for localized anti-inflammatory activity, anti-fungal activity, anti-viral activity, or combinations thereof. Such compositions possess a therapeutically effective amount of a non-betaine form ciprofloxacin (e.g., ciprofloxacin hydrochloride monohydrate); one of a pH adjusting agent and a preservative; water; and a pH from about 5.5 to about 10. In some embodiments, such compositions may be free or free of added skin permeation enhancer and/or contain a betaine form ciprofloxacin.Type: GrantFiled: July 14, 2015Date of Patent: July 19, 2016Inventors: Nilesh Parikh, William Crawford Hite
-
Patent number: 9387164Abstract: The present invention relates to ophthalmic preparations in the form of eyedrops based on BDNF (Brain-Derived Neurotrophic Factor). Said preparations can be administered topically to the intact eye surface, and are useful in the prevention and treatment of neurodegenerative disorders of the retina, optic nerve, lateral geniculate body and visual cortex, in order to prevent reduction of visual capacity and restore the normal visual function.Type: GrantFiled: November 12, 2010Date of Patent: July 12, 2016Assignee: HMFRA HUNGARY LIMITED LIABILITY COMPANYInventors: Luciano Domenici, Luca Giovannini, Marco Sanso′
-
Patent number: 9351991Abstract: An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.Type: GrantFiled: August 16, 2013Date of Patent: May 31, 2016Assignee: Theo Holdings, LLCInventor: John M. Szabocsik
-
Patent number: 9351990Abstract: An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.Type: GrantFiled: August 16, 2013Date of Patent: May 31, 2016Assignee: Theo Holdings, LLCInventor: John M. Szabocsik
-
Patent number: 9345714Abstract: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.Type: GrantFiled: August 28, 2015Date of Patent: May 24, 2016Assignee: Alcon Pharmaceuticals Ltd.Inventors: G. Michael Wall, Peter J. Conroy
-
Patent number: 9259429Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.Type: GrantFiled: August 19, 2014Date of Patent: February 16, 2016Assignee: Allergan, Inc.Inventors: Jeffrey L. Edelman, Kelly M. Harrison
-
Patent number: 9241900Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.Type: GrantFiled: November 10, 2011Date of Patent: January 26, 2016Assignee: NOVALIQ GMBHInventor: Clive G. Wilson
-
Patent number: 9181517Abstract: A composition for cleaning contact lenses and producing a removable visible discharge comprising: polyvinyl-alcohol; povidone; and an isotonic contact solution.Type: GrantFiled: August 20, 2014Date of Patent: November 10, 2015Inventor: Satoshi Takeuchi
-
Patent number: 9149555Abstract: The present invention relates to a lens care solution having 0.001 to about 5 weight percent of a low molecular weight amine of the general formula: where R1, R2, R3 and R4 are —H or low molecular weight radicals, and R5 is a low molecular weight radical, or salt thereof; an effective amount of a tonicity agent; and the balance water.Type: GrantFiled: April 25, 2013Date of Patent: October 6, 2015Assignee: FXS Ventures, LLCInventor: Francis X. Smith
-
Patent number: 9138481Abstract: The present invention is directed to cellulosic gel compositions having improved viscosity stability through the exclusion of particular antioxidants and/or the exclusion of chemical entities that tend to produce free radicals. Preferably, the composition is an ophthalmic cellulosic gel composition that is suitable as a multi-dose composition.Type: GrantFiled: November 28, 2012Date of Patent: September 22, 2015Assignee: Alcon Research, Ltd.Inventors: Gemma Torrella, Guadalupe Almera, Jordi Garcés
-
Patent number: 9119827Abstract: Disclosed is an ophthalmic composition which is characterized by containing (A) a vitamin A, (B) a polyoxyethylene polyoxypropylene glycol, and (C) an oil component that is selected from the group consisting of castor oil, soybean oil, sesame oil, peanut oil, olive oil, almond oil, wheat germ oil, corn oil, rapeseed oil, sunflower oil, purified lanolin and gel hydrocarbon.Type: GrantFiled: June 29, 2010Date of Patent: September 1, 2015Assignee: LION CORPORATIONInventors: Akito Odaka, Chieko Inoue, Manabu Hattori, Nobuhito Tabuchi
-
Patent number: 9089560Abstract: The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient for an extended duration while minimizing the occurrence of adverse side effects, such as eye redness during the patient's waking hours.Type: GrantFiled: January 31, 2014Date of Patent: July 28, 2015Assignee: Ocularis Pharma, LLCInventor: Alan Meyer
-
Patent number: 9044484Abstract: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate and a low concentration of benzalkonium chloride.Type: GrantFiled: June 17, 2010Date of Patent: June 2, 2015Assignee: Alcon Research, Ltd.Inventor: Bhagwati P. Kabra